AstraZeneca Aims To Shake Plavix Off The Throne With Launch Of Brilinta In China
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca launches Brilinta in China, aiming to grow its share of a $1.5 billion antithrombotic market at the expense of Sanofi’s Plavix.